Andere Kunden interessierten sich auch für
![DUCHENNE-KRANKHEIT: KOMPLEXITÄT BEI DER ANWENDUNG VON ATALUREN IN SPANIEN.]( "DUCHENNE-KRANKHEIT: KOMPLEXITÄT BEI DER ANWENDUNG VON ATALUREN IN SPANIEN.")
DUCHENNE-KRANKHEIT: KOMPLEXITÄT BEI DER ANWENDUNG VON ATALUREN IN SPANIEN.45,90 €![Measurement of biochemical parameters in community pharmacies]( "Measurement of biochemical parameters in community pharmacies")
Measurement of biochemical parameters in community pharmacies26,99 €![Outcome of Pharmaceutical care study among Saudi Hypertensive Patients]( "Outcome of Pharmaceutical care study among Saudi Hypertensive Patients")
Outcome of Pharmaceutical care study among Saudi Hypertensive Patients15,99 €![The Pediatric Lung]( "The Pediatric Lung")
The Pediatric Lung37,99 €![The Science and Ethics of Antipsychotic Use in Children]( "The Science and Ethics of Antipsychotic Use in Children")
The Science and Ethics of Antipsychotic Use in Children38,99 €![Starting Clinical Pharmacy Services in Sudan]( "Starting Clinical Pharmacy Services in Sudan")
Starting Clinical Pharmacy Services in Sudan16,99 €![The Pediatric Lung]( "The Pediatric Lung")
The Pediatric Lung59,99 €
Duchenne muscular dystrophy is a rare genetic disease which affects a small proportion of the population and for which there is currently only one authorized treatment; ataluren. Since this drug was approved, aspects such as its real efficacy, its financing and its use in the different countries of Europe and also in the different regions of Spain have been questioned. In our country, ataluren is not a financed drug, which prevents the public health system from treating affected children. This situation has generated a profound debate, in which ethical aspects such as equity and justice are involved, as well as some legal principles such as the protection of minors.